FGFR2 fusions and IDH1 mutations predict response to targeted inhibitors; MSI-H/dMMR status, PD-L1 positivity, and high tumor mutational burden correlate with improved immunotherapy outcomes; and BAP1 or BRCA1/2 alterations indicate sensitivity to PARP inhibition. This evidence concerns the gene BAP1 and neoplasm.